US › Healthcare

Atossa Genetics Inc (ATOS)

US · Healthcare · Biotechnology

$2.31+6.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-9.6M
Profit YoY
-42.7%
EPS
$-1.11
EPS estimate
$-1.22

EPS came in at -1.11 against a street estimate of -1.22 — a beat of 9.0%.

Key statistics

Market cap
$21.6M
Forward P/E
7.0
P/B
0.68
Book value
$3.54
EPS (TTM)
$-4.37
52-week high
$19.35
52-week low
$1.70
50-day MA
$3.01
200-day MA
$6.95
Beta
1.25

Analyst view

Analysts rate Atossa Genetics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $22.00.

Shareholding

Insiders
1.85%
Institutions
16.33%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC3.50%
Ameriprise Financial Inc2.56%
BlackRock Inc1.33%
Renaissance Technologies Corp1.09%
Geode Capital Management, LLC0.97%
UBS Group AG0.92%
Millennium Management LLC0.67%
Vanguard Fiduciary Trust Co0.52%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Atossa Genetics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.